The CENPM (Centromere Protein M) antibody is a crucial tool in studying the role of CENPM, a key component of the centromere/kinetochore complex essential for proper chromosome segregation during cell division. CENPM is part of the constitutive centromere-associated network (CCAN), which stabilizes kinetochore-microtubule interactions and ensures accurate mitotic checkpoint signaling. It plays a vital role in maintaining genomic stability by regulating the assembly and function of the kinetochore, particularly during the G2/M phase transition.
CENPM antibodies are widely used in research to investigate its expression, localization, and interactions in both normal and pathological contexts. In cancer biology, CENPM overexpression has been linked to tumorigenesis, as dysregulated chromosome segregation can drive genomic instability and aneuploidy. Studies using CENPM antibodies have revealed its upregulation in various cancers, including breast, liver, and lung cancers, correlating with poor prognosis and chemoresistance. These antibodies enable techniques like Western blotting, immunofluorescence, and immunohistochemistry to visualize CENPM's spatial distribution in cells and tissues.
Additionally, CENPM antibodies contribute to understanding congenital disorders related to centromere dysfunction. Their application in functional assays (e.g., ChIP-seq) helps map centromeric regions and dissect epigenetic regulation mechanisms. As research advances, CENPM antibodies remain pivotal in exploring cell cycle control, cancer biomarkers, and therapeutic targets for precision oncology.